Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
Recruiting · NCT06978829 · Registry updated 2025-05-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC | LA HNSCC | Recruiting | Phase 2 | 2025-05-18 | NCT06978829 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 46 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Chongqing | China | 1 |